Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious.

Shares of Pfizer Inc. PFE rallied 1.71% to $25.58 Wednesday, on what proved to be an all-around poor trading session for the ...

In the latest close session, Pfizer (PFE) was up +1.63% at $25.56. This move outpaced the S&P 500's daily loss of 0.53%. On the other hand, the Dow registered a loss of 0.09%, and the ...

Promising clinical results in 2026 could set the stage for Pfizer's stock to rebound. However, the company's COVID-19 product ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...

Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The ...

However, there's one potentially lucrative growth opportunity that Pfizer's focusing on that could change things and ...

Pfizer recently announced its guidance for 2026. One thing seems clear: Its financial results won't get much stronger. It ...

Pfizer Inc. (NYSE:PFE) ranks among the best stocks under $25 to buy now. Citing the company’s cautious 2026 outlook, BMO ...

From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going ...

Pfizer has beaten its earnings per share (EPS) estimates in its past 12 quarters. Beating EPS estimates hasn't always meant positive movements for Pfizer's share price. The stock's low valuation and ...